Abstract 6002
Background
Although cancer patients are known to be at higher risk of infection and its subsequent complications, the magnitude of infection-related mortality in cancer patients remains unknown. In this study, data from Surveillance, Epidemiology, and End Results Program (SEER) were explored in order to identify how far infection was identified as the cause of death in cancer patients in the United States between 2010 and 2016.
Methods
Data were obtained using SEER*Stat version 8.3.5 where (SEER 18 Regs Nov 2018 Submission) was used as the data source. Only cases with malignant behavior, known age, and those in research database were included. Analysis was made for patients who were diagnosed between 2010 and 2016 whose vital status was reported as "dead" at the time of study cut-off. Data about cause of death were exported using case-listing session in SEER*Stat and were analyzed using SPSS version 25.
Results
1,012,769 cases were included in the final data analysis. Infection was identified as the cause of death in 1.89% of cases (n = 19,155). Infection-related mortality was much higher in patients diagnosed with hematological malignancies (3.6%, n = 3,472) compared with non-hematological malignant diseases (1.7%, n = 15683). Deaths related to infection were also higher in males (2.2%, n = 11,827) compared with females (1.6%, n = 7,328).
Conclusions
Although infection is perceived as a major cause of morbidity and mortality in cancer patients, its current magnitude may be lower than expectations. Infection-related mortality showed higher prevelance in males and in patients with hematological malignancies.
Clinical trial identification
N/A
Editorial acknowledgement
N/A
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4228 - Clinical Evaluation of Drug-Eluting Bead Transcatheter Arterial Chemoembolization(D-TACE) versus Conventional TACE in Treatment of unresectable Hepatocellular Carcinoma
Presenter: Yi Chen
Session: Poster Display session 1
Resources:
Abstract
3930 - Safety profile of tepotinib in patients with advanced solid tumors: pooled analysis of phase I and II data
Presenter: Thomas Decaens
Session: Poster Display session 1
Resources:
Abstract
5373 - Drug-drug interaction profile of tepotinib with CYP3A and P-gp substrates
Presenter: Juergen Heuer
Session: Poster Display session 1
Resources:
Abstract
5455 - Bioavailability of tepotinib: impact of omeprazole and food
Presenter: Juergen Heuer
Session: Poster Display session 1
Resources:
Abstract
2618 - Tislelizumab Exposure-Response Analyses of Efficacy and Safety in Patients with Advanced Tumors
Presenter: Chi-Yuan Wu
Session: Poster Display session 1
Resources:
Abstract
2563 - Population Pharmacokinetics of Tislelizumab in Patients with Advanced Tumors
Presenter: Chi-Yuan Wu
Session: Poster Display session 1
Resources:
Abstract
2021 - The Addition of Metformin to Systemic Anticancer Therapy
Presenter: Jung Han Kim
Session: Poster Display session 1
Resources:
Abstract
5243 - Growth modulation index (GMI) as a comparative measure of clinical activity of larotrectinib versus prior systemic treatments in adult and pediatric TRK fusion cancer patients
Presenter: Antoine Italiano
Session: Poster Display session 1
Resources:
Abstract
598 - Analysis of the overall survival and main surrogates used for FDA approvals in solid and hematological malignancies.
Presenter: Maria Kleniewska-Wieczor
Session: Poster Display session 1
Resources:
Abstract
5381 - Comparison of intratumoral docetaxel exposure in cancer patients between nanoparticle entrapped docetaxel (CPC634) and conventional docetaxel (Cd): the CriTax study
Presenter: Ruben Van Eerden
Session: Poster Display session 1
Resources:
Abstract